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Abstract  
Trichilia hirta L. (Meliaceae) is traditionally used as antitumor source in Santiago de Cuba. Therefore, the aim of this study was to document and analyze the 
traditional medicinal use of this plant by cancer patients in Santiago de Cuba and to evaluate its antiproliferative activity on human normal and cancer cells. 
Cancer patients consuming Trichilia hirta extracts (Jubabán) were randomly selected and interviewed. The antiproliferative activity of a polysaccharide-rich 
fraction from leaves was evaluated against normal (MRC-5) and cancer cells (A-549, HeLa and Hep-2) by MTT assay. The study revealed that Trichilia hirta 
extracts are mainly used as anticancer source (46%). Moreover, the majority of cancer patients consuming Trichilia hirta extracts had carcinoma (86%). In 
particular, the most frequent were lung (26%) and prostate (18%) carcinoma. The majority (90%) of patients were consuming the extracts simultaneously, or 
after the chemotherapy and radiotherapy treatment. The polysaccharide-rich fraction showed antiproliferative activity against human lung cancer cells (A-
549) and human cervix carcinoma (HeLa) cancer cells. However, no toxicity was observed in human normal fibroblasts (MRC-5). These results suggest that 
polysaccharide-rich fraction from Trichilia hirta contribute to the antitumor properties of this specie. 
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Resumen 
Trichilia hirta L. (Meliaceae) es tradicionalmente usada como recurso antitumoral en Santiago de Cuba. Por lo que, el objetivo de este estudio fue documentar 
y analizar el uso tradicional de esta planta por pacientes con cáncer en Santiago de Cuba y evaluar su actividad antiproliferativa sobre células humanas 
normales y tumorales. Pacientes con cáncer consumiendo los extractos de Trichilia hirta (jubabán) fueron aleatoriamente seleccionados y entrevistados. La 
actividad antiproliferativa de la fracción rica en polisacáridos de hojas fue evaluada en células normales (MRC-5) y en células tumorales (A-549, HeLa y 
Hep-2) a través del ensayo con MTT. El estudio reveló que los extractos de Trichilia hirta eran usados mayoritariamente como recurso antitumoral (46%). 
Además, la mayoría de los pacientes consumiendo extractos de Trichilia hirta presentaron carcinoma (86%). En particular, los más frecuentes fueron 
carcinomas de pulmón (26%) y próstata (18%). También la mayoría de los pacientes (90%) consumieron los extractos simultáneamente o después de 
tratamientos con quimioterapia y radioterapia. La fracción rica en polisacáridos mostró actividad antiproliferativa contra las células de cáncer de pulmón 
humano (A-549) y carcinoma de cerviz humano (HeLa). Sin embargo, no se observó toxicidad en fibroblastos humanos normales (MRC-5). Estos resultados 
sugieren que la fracción rica en polisacáridos de hojas de Trichilia hirta contribuye a la actividad antitumoral de esta especie. 
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INTRODUCTION 
The documentation of knowledge is an essential step 
in ethnobiology as it provides data for further studies 
that may be driven by either philosophical or mostly 
utilitarian questions. The broad perspective of 
ethnopharmacology contextualizes ecology and 
addresses the perception of plants, plant use, 
pharmacology and physiology in human 
communities. Ethnopharmacology can be specifically 
relevant with respect to further developing and 
evaluating indigenous pharmacopoeias (Leonti, 
2011). Medicines from biologically active plants 
have a long history of use in both traditional and 
modern societies as herbal remedies or crude drugs, 
purified Food and Drug Administration (FDA)-
approved compounds, and as starting materials for 
further medicinal chemistry modifications. Moreover, 
the majority of new medicines derived from plant 
secondary metabolites have been applied toward the 
treatment and/or prevention of cancer (Balunas et al., 
2006). 
There are two main strategies for the 
selection of plant species in drug discovery: random 
screening and ethnomedical knowledge. The second 
approach includes plants used in organized traditional 
medical systems like herbalism, folklore and 
shamanism (Pieters and Vlietinck, 2005).  
Trichilia hirta L. (Meliaceae) is an important 
medicinal plant that is gaining popularity for treating 
various ailments, particularly against cancer. This 
plant is commonly known as Jubabán in Santiago de 
Cuba. It is also known in different countries as 
Broomstick, broomwood, cabo de hacha, cedrillo, 
cedrillo colorado, cedro macho, napahuite, red cedar 
and trompillo (Little and Wadsworth, 1964; Liogier, 
1988).  
This specie has traditionally been used as a 
remedy to treat cancer (Pettit et al., 1983), external 
ulcers (Roig, 1974) and respiratory disorders (Beyra 
et al., 2004). Its organic extracts have shown anti-
inflammatory activity related with COX-2 selective 
inhibition (Obukowicz and Hummert, 2004). The 
administration of Trichilia hirta extracts to Balb/c 
mice indicated that ethanol extract from this plant 
could exhibit leukocyte-stimulating properties that 
makes it a promising alternative for the development 
of an immunoprotective agent (Sosa et al., 2011). 
Popular information suggests that oral 
administration of Trichilia hirta root and leaf extracts 
improved the overall general well being in cancer 
patients (Hernández et al., 2004). These observations 
are motivating because the patients were terminally 
ill and had exhausted all the modern conventional 
therapies that included surgery, radiation and/or 
chemotherapy. 
In the current study, we investigated in detail 
and documented the treated illness with Trichilia 
hirta extracts, as well as the plant parts used, ways of 
remedy preparations, route of administration and 
dosage, side effects, and simultaneous use with 
oncological treatment. We also evaluated the 
cytotoxic activity of a polysaccharide-rich fraction 
from Trichilia hirta leaves on human normal and 
cancer cells in vitro. 
 
MATERIALS AND METHODS 
Study area 
Santiago de Cuba is the capital city of Santiago de 
Cuba Province in the south-eastern area of the island 
nation of Cuba, some 540 miles (870 km) south-east 
of the Cuban capital of Havana. It is situated between 
latitude 20° N, 01 N, longitude 75° W, and 50° W. 
The municipality extends over 1,023.8 square 
kilometers (395.3 sq mi). Historically Santiago de 
Cuba has long been the second most important city 
on the island after Havana, and remains the second 
largest. It is on a bay connected to the Caribbean Sea 
and is an important seaport. In 2009 the city of 
Santiago de Cuba had a population of about 727.449 
people (National office of statistics. Republic of 
Cuba, 2009). 
 
Data collection 
The study was conducted in eight local communities 
of Santiago de Cuba municipality. The communities 
were El Caney, Chicharrones, Versalles, Martí, Abel 
Santamaría, Vista Hermosa, Antonio Maceo and 30 
de Noviembre. A number of 53 cancer patients and 
herbalist consuming Trichilia hirta extracts (jubabán) 
were randomly selected and interviewed between 
February-May 2009 mainly through individual 
interviews using a semi-structured interview format. 
During the interview with each patient, information 
regarding the illness treated with Trichilia hirta 
extracts, the plant parts used, ways of remedy 
preparations, route of administration and dosage, 
maximum time of consumption, side effects observed 
during extract use, simultaneous application of 
oncological treatment (chemotherapy, radiotherapy, 
surgery) was gathered. Details about types of cancer 
and conventional treatments of patients were obtained 
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in collaboration with the Oncological Hospital of 
Santiago de Cuba. 
 
Plant material, extract preparation and 
phytochemical screening 
Trichilia hirta leaves were collected in Santiago de 
Cuba (Cuba) and identified by a specialist at the 
Eastern Center for Ecosystem and Biodiversity 
(BIOECO). A voucher specimen (BIOECO No. 
1078) was deposited at the herbarium of this 
institution.  
The polysaccharide fraction of Trichilia hirta 
leaves was isolated according to a published (Li et 
al., 2007) with some modifications. Briefly, 100 g of 
Trichilia hirta leaves were air-dried and extracted 
with boiling water (at a ratio of 1:10, w/v) for 30 min 
according to the traditional method used in Santiago 
de Cuba. The suspension was filtered under suction 
to remove the insoluble matter. The supernatant was 
then concentrated to about 50 mL by rotary 
evaporation (IKA RV Basic, Germany). Concentrated 
extracts were successively fractionated to remove 
lipids by maceration with chloroform and ethyl 
acetate, respectively. Both fractions of chloroform 
and ethyl acetate were eliminated and the water-
soluble residue was re-suspended in five volumes of 
95% ethanol and allowed to stand overnight to 
precipitate crude polysaccharides. The precipitate 
was finally centrifugated (300 × g for 20 min) to 
remove the supernatant. A stock solution (250 
g/mL) was prepared in dimethyl sulphoxide 
(DMSO) diluted in minimum essential medium 
(MEM) supplemented with 1x pen.strepto-fungizone 
and 10% heat inactivated fetal bovine serum (FBS). 
The final concentration of DMSO in each sample did 
not exceed 0.05% v/v. The total content of 
polysaccharides was measured by phenol-sulfuric 
method (Dubois et al., 1951). The crude 
polysaccharides contained 90% of total carbohydrate. 
 
IN VITRO DETERMINATION OF 
ANTIPROLIFERATIVE ACTIVITY 
Cell culture and treatment of HeLa, A-549 and 
MRC-5 cells 
Human cervix carcinoma (HeLa), lung carcinoma (A-
549), larynx carcinoma (Hep-2) and one type of 
normal human cell line, fibroblast cells (MRC-5), 
from the American Type Culture Collection (ATCC) 
were kindly provided by Alexis Díaz García from 
National Laboratory of Microbiology (Institute of 
Tropical Medicine ¨Pedro Kourí¨. Cuba). The cells 
were cultured as monolayer in MEM and grown at 37 
ºC in 5% CO2 with humidified air atmosphere. 
Cells were seeded in 96 well-plates (50 
μL/well at a density of 2.5×105 cells/mL) for 24 h. 
After the cell adherence, the supernatant was 
discarded and the extracts were added at 
concentrations of 8, 16, 30, 60 and 120 µg/mL into 
the wells for 72 h. Cells growing  in MEM with 
corresponding concentrations of DMSO (0.05%) 
were used as control.  
The 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyl tetrazolium bromide (MTT) assay, which is 
based on the conversion of the yellow tetrazolium 
salt-MTT, to purple-formazan crystals by 
metabolically active cells, provides a quantitative 
determination of viable cells (Shriram et al., 2010). 
After 72 h of treatment, 10 L of MTT solution (5 
mg/mL) were added to each well and incubated at 37º 
C for another three hours. At the end of incubation 
the medium was discarded. The formed formazan 
crystals were dissolved with 150 μL of DMSO and 
the absorbance was read on a spectrophotometer plate 
reader at 560 nm (BIO-RAD) with 630 nm reference 
wavelengths. The percent of cell viability was 
obtained using the following formula: 
Inhibition of cell viability (%) = (1- Treated cells/ Untreated cells) x 100
 
RESULTS AND DISCUSSION 
Extracts from Trichilia hirta are traditionally used to 
treat different diseases (Fig. 1). A previous study 
indicated that aqueous extracts from this plant were 
used to treat uterine fibroma, asthma, diabetes, 
arterial hypertension and cancer in Santiago de Cuba 
(Hernández et al., 2004). However, the spectrum of 
medicinal uses of these extracts has currently been 
expanded to treat arthritis, anemia, and parasitic 
infections (Figure 1).  
Ethnopharmaceutical investigations of 
Trichilia hirta extracts have indicated its use as 
abortifacient, astringent, emmenagogue, insecticide, 
poison, stimulant and Sudorific (Duke, 2012). Also, 
water extracts from Trichilia hirta leaves have been 
used as cicatrizing in Cuba (Roig, 1974), and 
anticatarrhal (Beyra et al., 2004). 
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Figure 1 
Illness treated with Trichilia hirta water extract in Santiago de Cuba. 
 
 
 
The information was obtained mainly through individual interviews with selected subjects using a semi-
structured interview format. 
 
The survey indicated that the traditional medicine 
users of Santiago de Cuba (Figure 1) mainly use 
Trichilia hirta extracts as anticancer source. This 
plant has similarly been used for the traditional 
treatment of cancer in Venezuela (Pettit et al., 1983). 
This result is coherent with the global increase of 
cancer incidence (Ferlay et al., 2010; Siegel et al., 
2011) and concurrent arise of herbal medicines use 
by cancer patients (Gratus et al., 2009; Cheng et al., 
2010; Ali-Shtayeh et al., 2011).  
Despite of the traditional use of Trichilia 
hirta, little is known about the patterns of use of this 
plant as anticancer source. Following this approach, 
the results of interviewing cancer patients in 
collaboration with the Oncological Hospital of 
Santiago de Cuba allowed us to know that Trichilia 
hirta extracts have mainly been used to treat 
carcinomas (86%) and leukemia (14%) (Figure 2A). 
Moreover, the results showed that extracts from this 
plant are generally consumed by patients with lung 
(26%) and prostate (18%) carcinomas, although 
patients with different anatomical location of 
carcinomas also consumed these extracts. 
The pattern of extracts preparation started 
with dry or fresh materials, although 70% of the plant 
material was reported to be dry and stored for a future 
use. The extracts were mostly prepared as decoction 
(100%) using water as solvent of extraction. 
Nevertheless, the quantities of plant material used to 
prepare the remedies and the time of decoctions were 
different for leaves and roots. People applied a 
decoction time of 5-10 minutes to prepare the extracts 
generally using a small quantity of leaves. However, 
in case of roots, people prepared the extracts applying 
a decoction time of 30-40 minutes and used a defined 
quantity of ¼ kg of roots. 
The water extracts of Trichilia hirta leaves 
and roots were taken orally (100%). This further 
highlights the importance of documentation of the 
intake mode of these substances as part of routine 
clerking and assessment of patients in order to avoid 
potential drug-herb-vitamin interactions, particularly 
in patients undergoing chemo or hormonal therapy 
(Chang et al., 2011). The majority of interviewed 
cancer patients (70%) consumed 6-8 ounce of 
Trichilia hirta extract three times per day, while the 
other 30% showed differences in frequencies and 
volume of extract consumption.  
The majority of cancer patients (90%) were 
taking the extracts before the meals; that empirically 
established pattern of consumption might contribute 
to a rapid absorption of active compounds of the 
extracts. In addition, the subjects suggested that 
taking the remedy daily for long periods helps to 
increase the effectiveness of the extracts. 
Consequently, the majority of patients (93%) were 
taking the Trichilia hirta extract daily up to four 
months. Although some people (7%) consumed the 
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extracts for a variable period from 15 days and up to six months.  
 
 
Figure 2 
Traditional use of Trichilia hirta extracts against cancer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
A) Types of cancer traditionally treated with Trichilia hirta (Jubabán) extracts. B) Location of carcinomas 
traditionally treated with Trichilia hirta extracts. The information was obtained mainly through individual 
interviews with selected patients using a semi-structured interview format. Details about types of cancer and 
conventional treatments of patients were obtained in collaboration with the Oncological Hospital of Santiago 
de Cuba. 
 
The observed effects during the consumption of 
Trichilia hirta extracts provide important information 
about the pharmacological and toxicological effects 
of these extracts. Patients described several positive 
effects: hyperactivity, euphoria, increased appetite. 
However, some patients (15%) described side effects 
like nausea, increased transpiration, pain and small 
bleeding. Previous studies support that herbal 
medicine are seen as being less likely to give rise to 
adverse side effects (Lynch and Berry, 2007). 
Regarding the previous idea, the majority of 
interviewed patients (70%) informed the decrease or 
loss of the side effects in a period of seven days, 
while some patients kept these negative symptoms 
during 15 days. However, herbal medicines are 
usually a mixture of many active ingredients, which 
increases the likelihood of harm (Izzo and Ernst, 
2009).  
Cancer patients are commonly under a state 
of immunosuppression induced by tumor itself 
(Williams et al., 2004; Whelan and Scadden, 2006) 
and chemotherapy increases this altered state. Thus, 
the common purposes of concurrent administration of 
an herb with chemotherapy are to enhance the 
efficacy and/or to reduce the side effects of 
chemotherapy (Cheng et al., 2010). In this context, 
decoctions of Trichilia hirta roots have shown 
immunoprotective activity on Balb/c mice treated 
with 5-Fluorouracil (Hernández et al., 2010). 
Moreover, reports indicate that cancer patients 
perceive that boosting of the immune system will 
increase the chances of healing or survival treatment 
(Humpel and Jones, 2006). Thus, the immunological 
effect of Trichilia hirta extracts suggests a positive 
herb-drug interaction and supports the use of those 
extracts by cancer patients under chemotherapy 
treatment. 
Most of interviewed patients (90%) were 
taking the extracts of Trichilia hirta simultaneously, 
or after the chemotherapy and radiotherapy treatment. 
Similar surveys have shown an increased popularity 
of concurrent application of herbal remedies with 
conventional treatment (chemotherapy, radiation, or 
surgery) among cancer patients (Richardson et al., 
2000; Engdal et al., 2008). However, herbal remedies 
are usually complex mixtures of chemical entities 
that may display positive or negative herb-drugs 
interactions (Ernst, 2004; Unger, 2010). In 
consequence, the concern for these potential 
interactions is growing (Beijnen and Schellens, 2004; 
Izzo and Ernst, 2009) and Trichilia hirta is not and 
exception. Therefore, the mentioned side effects 
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during the consumption of Trichilia hirta extracts and 
possible herb-drugs interactions indicate the need of 
future toxicological studies to determine the safety of 
Trichilia hirta extracts. 
Most of the interviewed persons mentioned 
the assumed anticancer effect of these extracts. 
Moreover, a small part (10%) of interviewed cancer 
patients was taking Trichilia hirta roots and leaf 
extracts without any oncological treatment. This 
observation is motivating because these patients were 
terminally ill and had exhausted all the modern 
conventional therapies, that is, surgery, radiation 
and/or chemotherapy.  
The results indicated that Trichilia hirta roots 
are generally used to prepare the aqueous extracts 
(80%). In addition, cancer patients are currently using 
leaves to prepare extracts (20%). The incorporation 
of Trichilia hirta leaves to medicinal practices 
against cancer could be due to its relative ease to 
collect in comparison with the huge effort required to 
collect roots. Interestingly, the use of leaves in the 
preparation of remedies is common elsewhere 
(Liogier, 1974; Beyra et al., 2004). Besides, leaves 
remain green and plenty for most months of the year 
in Cuba. Therefore, the patients informed that use of 
leaves as anticancer source is rapidly growing. 
Our research group identified in previous 
studies that aqueous extracts from Trichilia hirta 
leaves extracts have antiproliferative activity on 
human melanoma cells (SK-mel-3) and human 
adenocarcinoma cells (T-47D) (data not shown). 
However, the contribution of some polar fractions to 
this activity needed further research. In order to 
assess this activity, a polysaccharide-rich fraction 
from leaves was assayed on human cervix carcinoma 
(HeLa), lung carcinoma (A-549), larynx carcinoma 
(Hep-2) and one type of normal human cell line, 
fibroblast cells (MRC-5).  
 
Figure 3 
Cell viability of human normal and cancer cells treated with polysaccharide rich fraction of Trichilia hirta. 
 
Cells were treated with 8, 16, 30, 60 and 120 µg/mL of extract for 72 h and the cell viability was determined 
by MTT assay. Cells without treatment and normal human fibroblast cells (MRC-5) were used as controls. 
The results were expressed as percent of inhibition of proliferation. 
 
The polysaccharide-rich fraction showed 
antiproliferative activity against human carcinomas 
cell lines of lung (A-549) and cervix (HeLa). The 
higher inhibition of the proliferation was observed at 
120 g/mL on A549 (54%) and HeLa (67%) cancer 
cell lines (Fig 3). Moreover, a slight antiproliferative 
effect was displayed on HeLa with 30 g/mL and 60 
g/mL respectively. Although, the laryngeal 
carcinoma cells (Hep-2) were less sensitive to the 
extract, a previous study showed in vitro cytotoxic 
activity of aqueous extract from Trichilia hirta roots 
on human T-47D breast carcinoma and SK-mel-3 
human melanoma (Hernández et al., 2010).  
The observed inhibitory activity on human 
lung carcinoma cells is encouraging because the 
majority of interviewed cancer patient currently 
consuming extracts from Trichilia hirta had lung 
carcinoma (Figure 2). These results suggest the 
hypothesis that Trichilia hirta extracts could be 
useful for treating cancer, particularly lung 
carcinomas. 
Despite of those antiproliferative activities, 
the effect of polysaccharide-rich fraction from 
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Trichilia hirta leaves was highly selective for cancer 
cells. This observation was supported by the lack of 
toxicity on human normal fibroblast. These cells 
showed a normal proliferation compared with control 
when they were treated with the polysaccharide-rich 
fraction. Similar results have been observed in a 
previous study, where aqueous extracts from 
Trichilia hirta showed a selective antiproliferative 
activity against cancer cells (Hernández et al., 2010).  
The selectivity of Trichilia hirta 
polysaccharide-rich fraction could be associated to 
the diversity of biological activities that 
polysaccharides can exhibit. The polysaccharides are 
exogenous biological response modifiers (BRMs) and 
several exogenous BRMs have been reported to have 
anti-viral, anti-bacterial, anti-fungal, anti-parasitic, 
immunostimulant and anti-tumor activities (Leung et 
al., 2006). Thus, polysaccharides could affect the 
proliferation of cancer cells and protect normal cells. 
Some studies have shown the potential anti-cancer 
activity of polysaccharides from medicinal plants, 
among them, crude Orostachys japonicus 
polysaccharide extract displayed remarkable anti-
proliferative activity in HT-29 human colon cancer 
cells via apoptosis and various apoptosis-aiding 
activities (Deok-Seon et al., 2010). Crude 
polysaccharides from Salicornia herbacea showed 
anti-proliferative effect on HT-29 human colon 
cancer cells (Deok-Seon et al., 2009). Those studies 
suggested that polysaccharide extracts could have 
antiproliferative activity on cancer cells through the 
down-regulation of several genes involved in anti-
apoptotic activity, cell proliferation and cell cycle 
regulation, and up-regulation of the expression levels 
of several genes involved in apoptosis, tumor 
suppression. 
On the other hand, polysaccharides can 
stimulate or protect normal cells. For instance, 
polysaccharides isolated from Salicornia herbacea 
significantly induced NO production in the mouse 
macrophage line RAW 264.7. The effect of those 
polysaccharides suggested that those compounds may 
represent useful immunopotentiating agents (Lee et 
al., 2006). The Lycium barbarum polysaccharides 
can be used in compensating the decline in total 
antioxidant capacity, immune function and the 
activities of antioxidant enzymes and thereby reduces 
the risks of lipid peroxidation accelerated by age-
induced free radical (Li et al., 2007). Polysaccharide-
enriched fractions from the root of Radix Angelica 
sisnensis (APS) significantly enhanced not only the 
recovery of platelets, other blood cells and their 
progenitor cells, but also the formation of Colony 
Forming Unit (CFU) in the mouse model. In addition, 
APS showed antiapoptotic effect in a megakaryocytic 
cell line cells (M-07e) (Liu et al., 2010). 
Currently, most medicines used in 
chemotherapy are combinations of chemical 
substances with no selectivity toward cancer cells and 
usually show toxicity to normal cells as well. 
Therefore, in recent years, many studies have 
attempted to identify new drugs candidates that are 
selective toward cancer cells to avoid damaging 
normal cells. The combination of the antiproliferative 
activity of Trichilia hirta polysaccharide-rich fraction 
on cancer cells and less cellular toxicity to normal 
cells (MRC-5) suggests that this fraction could be a 
possible candidate to be investigated for their 
synergistic effects in combination with chemical 
substances.  
The anticancer activities of several genera 
belonging to Meliaceae have been studied and have 
yielded benzofurans and terpenoids as the major 
active constituents (Cragg et al., 2006). However, 
those compounds are mainly extracted in 
dichloromethane (Pupo et al., 2002) and have little 
solubility in water. Thus, our results suggest that 
polysaccharide-rich fraction from Trichilia hirta also 
contribute to the antitumor properties of this plant. 
Several polysaccharides derived from higher plants 
are relatively non-toxic and do not cause significant 
side effects. Therefore, plant polysaccharides could 
be good candidates for therapeutics with antitumor 
effects and low toxicity  (Schepetkin and Quinn, 
2006).  
This study showed that Trichilia hirta 
(jubabán) is used by the traditional medicine of 
Santiago de Cuba for treating several illnesses. 
Besides, this plant is playing a significant role as 
complementary source for cancer patients with lung 
and prostate carcinoma. Roots and leaves are used for 
the preparation of extracts, which, are frequently 
taken together with chemotherapy and radiotherapy 
treatment as a complementary anticancer source. 
Moreover, the polysaccharide-rich fraction from 
Trichilia hirta leaves showed selective 
antiproliferative activity on human cancer cells. 
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